GlassScriptPhysician profile
Aurora Jankowiak
NPI 1144823105
$1,753.02
in general payments reported to CMS, 2019-2025
26 companies · $49.68 in 2025
The $49.68 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $527 · 2023: $1,109 · 2024: $67.13 · 2025: $49.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $326.23 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $232.62 | 2022-2023 | |
| Radius Health, INC. | $145.97 | 2023 | Tymlos |
| Novo Nordisk INC | $108.03 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $104.62 | 2022 | |
| Exact Sciences Corporation | $102.58 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $83.73 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $59.07 | 2022-2023 | |
| Astellas Pharma US INC | $58.25 | 2023-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $55.67 | 2022-2023 | |
| Pfizer INC. | $55.25 | 2023 | |
| Glaxosmithkline, LLC. | $53.89 | 2022-2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $45.36 | 2022-2023 | Breztri |
| Dexcom, INC. | $44.96 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $41.70 | 2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $33.39 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $32.53 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $27.88 | 2022-2023 | Contrave, Onzetra Xsail |
| Tolmar, INC. | $24.34 | 2023 | |
| Hologic Sales and Service, LLC | $20.86 | 2023 | Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.85 | 2024 | |
| Vivus LLC | $19.27 | 2023 | Qsymia |
| Sanofi Pasteur INC. | $15.61 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.85 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.48 | 2023 | Xarelto |
| Arbor Pharmaceuticals, INC. | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurora Jankowiak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.